Cargando…

Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis

BACKGROUND: Lung disease phenotype varies widely even in the F508del (homozygous) genotype. Leukocyte-driven inflammation is important for pulmonary disease pathogenesis in cystic fibrosis (CF). Blood cytokines correlate negatively with pulmonary function in F508del homozygous patients, and gap junc...

Descripción completa

Detalles Bibliográficos
Autores principales: Horn, Tabea, Ludwig, Michael, Eickmeier, Olaf, Neerinex, Anne H., Maitland-van der Zee, Anke H., Smaczny, Christina, Wagner, Thomas O. F., Schubert, Ralf, Zielen, Stefan, Majoor, Christof, Bos, Lieuwe D., Schmitt-Grohé, Sabina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655539/
https://www.ncbi.nlm.nih.gov/pubmed/33193670
http://dx.doi.org/10.3389/fgene.2020.570403
_version_ 1783608220941549568
author Horn, Tabea
Ludwig, Michael
Eickmeier, Olaf
Neerinex, Anne H.
Maitland-van der Zee, Anke H.
Smaczny, Christina
Wagner, Thomas O. F.
Schubert, Ralf
Zielen, Stefan
Majoor, Christof
Bos, Lieuwe D.
Schmitt-Grohé, Sabina
author_facet Horn, Tabea
Ludwig, Michael
Eickmeier, Olaf
Neerinex, Anne H.
Maitland-van der Zee, Anke H.
Smaczny, Christina
Wagner, Thomas O. F.
Schubert, Ralf
Zielen, Stefan
Majoor, Christof
Bos, Lieuwe D.
Schmitt-Grohé, Sabina
author_sort Horn, Tabea
collection PubMed
description BACKGROUND: Lung disease phenotype varies widely even in the F508del (homozygous) genotype. Leukocyte-driven inflammation is important for pulmonary disease pathogenesis in cystic fibrosis (CF). Blood cytokines correlate negatively with pulmonary function in F508del homozygous patients, and gap junction proteins (GJA) might be related to the influx of blood cells into the lung and influence disease course. We aimed to assess the relationship between GJA1/GJA4 genotypes and the clinical disease phenotype. METHODS: One-hundred-and-sixteen homozygous F508del patients (mean age 27 years, m/f 66/50) were recruited from the CF centers of Bonn, Frankfurt, and Amsterdam. Sequence analysis was performed for GJA1 and GJA4. The clinical disease course was assessed over 3 years using pulmonary function tests, body mass index, Pseudomonas aeruginosa colonization, diabetes mellitus, survival to end-stage lung disease, blood and sputum inflammatory markers. RESULTS: Sequence analysis revealed one clinically relevant single nucleotide polymorphism. In this GJA4 variant (rs41266431), homozygous G variant carriers (n = 84/116; 72.4%) had poorer pulmonary function (FVC% pred: mean 78/86, p < 0.040) and survival to end-stage lung disease was lower (p < 0.029). The frequency of P. aeruginosa colonization was not influenced by the genotype, but in those chronically colonized, those with the G/G genotype had reduced pulmonary function (FVC% pred: mean 67/80, p < 0.049). Serum interleukin-8 (median: 12.4/6.7 pg/ml, p < 0.052) and sputum leukocytes (2305/437.5 pg/ml, p < 0.025) were higher for the G/G genotype. CONCLUSIONS: In carriers of the A allele (27.6%) the GJA4 variant is associated with significantly better protection against end-stage lung disease and superior pulmonary function test results in F508del homozygous patients. This SNP has the potential of a modifier gene for phenotyping severity of CF lung disease, in addition to the CFTR genotype. CLINICAL TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov, number NCT04242420, retrospectively on January 24th, 2020.
format Online
Article
Text
id pubmed-7655539
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76555392020-11-13 Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis Horn, Tabea Ludwig, Michael Eickmeier, Olaf Neerinex, Anne H. Maitland-van der Zee, Anke H. Smaczny, Christina Wagner, Thomas O. F. Schubert, Ralf Zielen, Stefan Majoor, Christof Bos, Lieuwe D. Schmitt-Grohé, Sabina Front Genet Genetics BACKGROUND: Lung disease phenotype varies widely even in the F508del (homozygous) genotype. Leukocyte-driven inflammation is important for pulmonary disease pathogenesis in cystic fibrosis (CF). Blood cytokines correlate negatively with pulmonary function in F508del homozygous patients, and gap junction proteins (GJA) might be related to the influx of blood cells into the lung and influence disease course. We aimed to assess the relationship between GJA1/GJA4 genotypes and the clinical disease phenotype. METHODS: One-hundred-and-sixteen homozygous F508del patients (mean age 27 years, m/f 66/50) were recruited from the CF centers of Bonn, Frankfurt, and Amsterdam. Sequence analysis was performed for GJA1 and GJA4. The clinical disease course was assessed over 3 years using pulmonary function tests, body mass index, Pseudomonas aeruginosa colonization, diabetes mellitus, survival to end-stage lung disease, blood and sputum inflammatory markers. RESULTS: Sequence analysis revealed one clinically relevant single nucleotide polymorphism. In this GJA4 variant (rs41266431), homozygous G variant carriers (n = 84/116; 72.4%) had poorer pulmonary function (FVC% pred: mean 78/86, p < 0.040) and survival to end-stage lung disease was lower (p < 0.029). The frequency of P. aeruginosa colonization was not influenced by the genotype, but in those chronically colonized, those with the G/G genotype had reduced pulmonary function (FVC% pred: mean 67/80, p < 0.049). Serum interleukin-8 (median: 12.4/6.7 pg/ml, p < 0.052) and sputum leukocytes (2305/437.5 pg/ml, p < 0.025) were higher for the G/G genotype. CONCLUSIONS: In carriers of the A allele (27.6%) the GJA4 variant is associated with significantly better protection against end-stage lung disease and superior pulmonary function test results in F508del homozygous patients. This SNP has the potential of a modifier gene for phenotyping severity of CF lung disease, in addition to the CFTR genotype. CLINICAL TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov, number NCT04242420, retrospectively on January 24th, 2020. Frontiers Media S.A. 2020-10-28 /pmc/articles/PMC7655539/ /pubmed/33193670 http://dx.doi.org/10.3389/fgene.2020.570403 Text en Copyright © 2020 Horn, Ludwig, Eickmeier, Neerinex, Maitland-van der Zee, Smaczny, Wagner, Schubert, Zielen, Majoor, Bos and Schmitt-Grohé. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Horn, Tabea
Ludwig, Michael
Eickmeier, Olaf
Neerinex, Anne H.
Maitland-van der Zee, Anke H.
Smaczny, Christina
Wagner, Thomas O. F.
Schubert, Ralf
Zielen, Stefan
Majoor, Christof
Bos, Lieuwe D.
Schmitt-Grohé, Sabina
Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
title Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
title_full Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
title_fullStr Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
title_full_unstemmed Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
title_short Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
title_sort impact of a gap junction protein alpha 4 variant on clinical disease phenotype in f508del homozygous patients with cystic fibrosis
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655539/
https://www.ncbi.nlm.nih.gov/pubmed/33193670
http://dx.doi.org/10.3389/fgene.2020.570403
work_keys_str_mv AT horntabea impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT ludwigmichael impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT eickmeierolaf impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT neerinexanneh impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT maitlandvanderzeeankeh impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT smacznychristina impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT wagnerthomasof impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT schubertralf impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT zielenstefan impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT majoorchristof impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT boslieuwed impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis
AT schmittgrohesabina impactofagapjunctionproteinalpha4variantonclinicaldiseasephenotypeinf508delhomozygouspatientswithcysticfibrosis